Trials.ai was born from a deeply personal mission. When our founder's closest friend Paul was diagnosed with pancreatic cancer and given just five months to live, we reached out to colleagues across the industry. The response was heartbreaking: promising treatments existed, but the trials wouldn't be designed in time. Paul passed away eight months after his diagnosis, and that loss ignited a determination to dismantle the archaic, slow-moving processes that stand between patients and the treatments they desperately need.
Founded in San Diego, Trials.ai was built on the belief that clinical trial design should be driven by data, not documents. Our team of clinical scientists, data engineers, and AI researchers set out to build the intelligent infrastructure that the industry was missing - a clinical information highway connecting protocols, data, and systems.
In 2023, ZS acquired Trials.ai, combining our AI-powered platform with ZS's four decades of life sciences expertise and a global network serving the world's leading pharmaceutical companies. Together, we're accelerating the path from study concept to patient impact. Because patients don't have time to wait.
As part of ZS, we operate within a global firm of over 13,000 professionals across more than 35 offices in North America, South America, Europe, and Asia-Pacific - bringing four decades of life sciences expertise to every engagement.
